Noah Stansfield

Preliminary data from an ongoing clinical trial suggest that AVR-RD-04 has been well-tolerated.

In a mouse model of MPS II, IDS.ApoEII effected completely normalized brain pathology and behavior.

Adverum Biotechnologies’ multicenter, double-masked LUNA trial will enroll 72 patients aged 50 years or older.

A substantial benefit noted for EtranaDez and val-rox is that they are delivered as a single-dose.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

In nonclinical studies, AK-OTOF was well-tolerated in both mice and non-human primates.

The disease models used also helped to establish the function of NPHP5 in cilia morphogenesis.

The announcement comes after positive top-line results in the ongoing KarMMa-3 study.

Improved functional activity compared to ROR-1-targeted CAR-T therapies without the 2 forms of reprogramming was demonstrated in preclinical studies.

Of the 8 treated patients who were evaluable, 6 patients had stable disease at Day 28.

Among the 31 patients evaluable for efficacy analysis, ORR was 100%.

SLN124 was well-tolerated in a previous clinical trial involving healthy volunteers.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

Of 55 evaluable patients in ZUMA-3, 71% achieved complete remission (CR) or CR with incomplete hematological recovery (CRi).

Immusoft plans to begin the phase 1 clinical trial of ISP-001 before the end of 2022.

The study’s primary end points are change in visual acuity and the occurrence of adverse events.

The risk-benefit assessment determined that there are no significant safety concerns.

RGX-121 was well-tolerated across all 3 of the dose cohorts with no treatment-related serious adverse events reported.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

A pre-treatment TME with high levels of cytokines and chemokines was associated with complete response to axi-cel treatment.

In an ovarian cancer mouse model, the combination therapy group showed an 83% increase in survival duration compared to an untreated group.

The study will be carried out in Paris and is expected to begin before the end of the year.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

A case study showed that the patient achieved a complete response in 12 months after treatment with CARsgen Therapeutics’ cell therapy.

Thirty-five patients were previously treated with Innovative Cellular Therapeutics’ GCC19CART in an IRB-approved trial in China.

All patients with NMOSD who received CT103A showed improved Expanded Disability Status Scale scores.

The BLA was supported by data from 2 intrapatient, placebo-controlled clinical trials.

Higher doses were associated with improved overall survival, event-free survival, and relapse-free survival.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

The novel therapy targets a hormone receptor only expressed at immunologically relevant levels in the ovaries.